PMID- 21130506
OWN - NLM
STAT- MEDLINE
DCOM- 20110509
LR  - 20220129
IS  - 1873-3735 (Electronic)
IS  - 0165-6147 (Linking)
VI  - 32
IP  - 1
DP  - 2011 Jan
TI  - Emerging therapies in the treatment of 'diabesity': beyond GLP-1.
PG  - 8-15
LID - 10.1016/j.tips.2010.10.003 [doi]
AB  - Bariatric surgery has proven to be an effective means of treating 'diabesity': 
      the combination of type 2 diabetes mellitus (T2DM) and obesity. The effects of 
      surgery go beyond weight loss but reflect a complex alteration in secretion of 
      gut hormones. Finding a pharmaceutical alternative that mimics the benefits of 
      surgery without surgical complications has become the 'holy grail' of the 
      twenty-first century. As knowledge of the multifaceted functions of gut hormones 
      increases, a multitude of drugs that exploit these actions has emerged. In this 
      review, we examine the current understanding of the mechanisms by which bariatric 
      surgery improves diabesity. We also discuss the rapidly emerging role of 
      glucagon-like peptide-1-based treatments as well as the potential for new 
      therapeutics based on other gut hormones (e.g. oxyntomodulin, peptide YY, gastric 
      inhibitory peptide, ghrelin).
CI  - Copyright A(c) 2010 Elsevier Ltd. All rights reserved.
FAU - Tharakan, George
AU  - Tharakan G
AD  - Department of Investigative Medicine, Division of Diabetes, Endocrinology and 
      Metabolism, Imperial College London, Sixth Floor, Commonwealth Building, London 
      W12 0HS, UK.
FAU - Tan, Tricia
AU  - Tan T
FAU - Bloom, Stephen
AU  - Bloom S
LA  - eng
GR  - G1000474/MRC_/Medical Research Council/United Kingdom
GR  - G7811974/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Review
DEP - 20101203
PL  - England
TA  - Trends Pharmacol Sci
JT  - Trends in pharmacological sciences
JID - 7906158
RN  - 0 (Gastrointestinal Hormones)
RN  - 0 (Ghrelin)
RN  - 0 (Receptors, Gastrointestinal Hormone)
RN  - 0 (Receptors, Ghrelin)
SB  - IM
MH  - Animals
MH  - Bariatric Surgery/adverse effects
MH  - Diabetes Mellitus, Type 2/*complications/*drug therapy/metabolism/surgery
MH  - Gastrointestinal Hormones/agonists/antagonists & inhibitors/*metabolism
MH  - Ghrelin/antagonists & inhibitors/metabolism
MH  - Humans
MH  - Molecular Targeted Therapy
MH  - Obesity/*complications/*drug therapy/metabolism/physiopathology/surgery
MH  - Receptors, Gastrointestinal Hormone/agonists/antagonists & inhibitors/*metabolism
MH  - Receptors, Ghrelin/antagonists & inhibitors/metabolism
EDAT- 2010/12/07 06:00
MHDA- 2011/05/10 06:00
CRDT- 2010/12/07 06:00
PHST- 2010/09/02 00:00 [received]
PHST- 2010/10/25 00:00 [revised]
PHST- 2010/10/27 00:00 [accepted]
PHST- 2010/12/07 06:00 [entrez]
PHST- 2010/12/07 06:00 [pubmed]
PHST- 2011/05/10 06:00 [medline]
AID - S0165-6147(10)00190-2 [pii]
AID - 10.1016/j.tips.2010.10.003 [doi]
PST - ppublish
SO  - Trends Pharmacol Sci. 2011 Jan;32(1):8-15. doi: 10.1016/j.tips.2010.10.003. Epub 
      2010 Dec 3.